Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Wijsenbeek (Rotterdam, Netherlands), E. Santermans (Mechelen, Belgium), P. Ford (Mechelen, Belgium), M. Kreuter (Heidelberg, Germany), N. Verbruggen (Mechelen, Belgium), P. Meyvisch (Mechelen, Belgium), W. Wuyts (Leuven, Belgium), K. Brown (Denver, CO, United States of America), D. Lederer (New York, NY, United States of America), T. Maher (London, United Kingdom). Forced vital capacity (FVC) decline in idiopathic pulmonary fibrosis (IPF) – modelling the myth. 1733

Member's Comments

No comment yet.

Related content which might interest you: Spirometric evaluation of idiopathic pulmonary fibrosis (IPF): forced or slow vital capacity? Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia Year: 2019 Forced vital capacity, total lung capacity and diffusion capacity in idiopathic pulmonary fibrosis Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 Analysis of patients with idiopathic pulmonary fibrosis (IPF) with percent predicted forced vital capacity (FVC)<50% treated with pirfenidone (PFD) in RECAP Source: International Congress 2016 – IPF treatment I Year: 2016 Forced expiratory volume in one second (FEV1) and peak expiratory flow (PEF): is there a correlation in chronic obstructive pulmonary disease (COPD) patients? Source: Eur Respir J 2001; 18: Suppl. 33, 213s Year: 2001 Treatment with corticosteroids and yearly decline of forced expiratory flow (FEV1) in patients with severe chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Respiratory structure and function Year: 2008 Percent predicted forced vital capacity (FVC) is a reliable, valid, and responsive measure of clinical status in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - Clinical issues in idiopathic pulmonary fibrosis Year: 2010 Monocyte count and decline in forced vital capacity (FVC) in patients with IPF Source: Virtual Congress 2020 – Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis Year: 2020 Differences in FVC decline by extent of emphysema in patients with combined pulmonary fibrosis and emphysema (CPFE) syndrome Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 FEV6 or FVC to detect airway obstruction in the community setting? Source: Annual Congress 2007 - PG17 - Lung function measurement in the community Year: 2007 Forced inspiratory volume in one second (FIV1) in the assessment of reversibility of airway obstruction in patients with chronic obstructive pulmonary disease (COPD) and in relation to the severity Source: Eur Respir J 2002; 20: Suppl. 38, 300s Year: 2002 The relationship between peak expiratory flow rate (PEFR) and forced expiratroy volume in the first second (FEV1) at low levels of FEV1. Implications for the assessment of COPD (chronic obstructive pulmonary disease) in primary care Source: Eur Respir J 2002; 20: Suppl. 38, 397s Year: 2002 Correlation between spirometric indices (FEV1, FVC) and lung diffusion values (DLCO) in subjects with varying severity of chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2007 - Primary care respiratory problems Year: 2007 Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 52 (2) 1702593; 10.1183/13993003.02593-2017 Year: 2018 Forced vital capacity decreases rapidly in patients with idiopathic upper lobe-dominant pulmonary fibrosis Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases Year: 2011 Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis Source: Eur Respir J 2010; 35: 830-836 Year: 2010 Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis Source: Eur Respir J 2012; 40: 61-66 Year: 2012 Does rapid decline predict poor prognosis? Source: Annual Congress 2007 - Rapid decline in lung function and its consequences Year: 2007 Real World experiences: Pirfenidone is well tolerated and reduces decline in FVC and TLCO at 9 months in IPF Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Are FEV6, FVC and VC different in diagnosing obstructive ventilatory defect? Source: International Congress 2019 – Physiologic assessment of airway diseases Year: 2019 Effect of baseline FVC on lung function decline with nintedanib in patients with IPF Source: International Congress 2015 – Treatment of IPF Year: 2015